MonoSol must face states’ Suboxone complaint
Just two weeks after dismissing Reckitt Benckiser Healthcare from an antitrust lawsuit alleging it monopolised the production of its opioid treatment drug Suboxone, a federal judge in Pennsylvania ruled that co-defendant MonoSol must face the claims.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10